According to DataM Intelligence, the Prostate Cancer Drugs Market Size reached USD 13.22 billion in 2024 and is projected to ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumor’s growth.

Rates of overall survival, prostate cancer-specific death, and distant metastasis were similar in patients who received prophylactic whole pelvic radiotherapy compared to those who received ...

A major rethink in the cost-effectiveness of a prostate cancer treatment could help thousands of patients while saving the ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says ...

Oncologists and urologists identified several barriers to treatment intensification for metastatic castration-sensitive ...

The testosterone threshold should be less than 10 ng/dL rather than less than 50 ng/dL for gauging advanced prostate cancer prognosis in patients on ADT. Examining sustained testosterone suppression ...

Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...